

The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2020-4318
Date:	10 June 2020
Product Name:	Golimumab/Infliximab
Therapeutic Area:	Immunology
Product Class:	Antirheumatic Agents - Biologic Response Modifiers
Condition(s) Studied:	Active Ulcerative Colitis
Protocol Number(s) and Title(s):	<p>NCT00487539 - C0524T17 A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis</p> <p>NCT00488631 - C0524T18 A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis</p> <p>NCT01863771 - CNT0148UCO3001 A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis</p> <p>NCT00036439 - C0168T37 A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis</p> <p>NCT00096655 - C0168T46 A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis</p> <p>NCT01551290 - REMICADEUCO3001 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis</p>
Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	

The YODA Project
Research Proposal Due Diligence Assessment

Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes
Part 4: Proposal Review	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	